Next 10 |
home / stock / mmedf / mmedf news
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It wasn’t long before marijuana was considered a taboo. Emerging science, however, has altered customer perceptions and has paved a path for its legalization. As a result, the global legal marijuana market continues ...
NEW YORK, June 9, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (NEO: MMED)(OTC:MMEDF)(DE: BGHM) (the “Company”), a leading clinical-stage pharmaceutical company and pioneer in the field of psychedelic inspired medicines, announces that J.R. Rahn, the Com...
Last week, Deepak Chopra revealed that he’d entered into a new partnership with MindMed (NEO: MMED) (OTCQB: MMEDF), which aligned with his continued interest in mind-body healing. MindMed is a clinical-stage biotech company that is researching psychedelic medicine. In his stat...
NEW YORK, May 27, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NEO: MMED)(OTC:MMEDF)(DE: BGHM)("MindMed" or the "Company") is pleased to announce that each of the resolutions put before the annual and special meeting of shareholders held today (the "Meeting") was pa...
NEW YORK, May 26, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (NEO: MMED)(OTC:MMEDF)(DE: BGHM), a leading psychedelic medicine biotech company, announced today the publication of the first pharmacogenetic data on LSD to help personalize dosing. The study results from...
NEW YORK, May 24, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (NEO: MMED)(OTC:MMEDF)(DE: BGHM), a leading clinical-stage psychedelic medicine company, and Nextage Therapeutics (TASE: NXTG), an Israeli innovative drug development company, announced the execution of a Me...
BASEL, Switzerland, May 20, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NEO: MMED)(OTC:MMEDF)(DE: BGHM), a leading clinical-stage psychedelic medicine company, announced today the approval by the local Swiss ethics committee of the first clinical trial evaluating the acute ...
NEW YORK, May 18, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NEO: MMED) (OTC:MMEDF)(DE: BGHM) ("MindMed" or the "Company"), a leading clinical-stage psychedelic medicine company, today announced it has entered into a letter of intent to partner with The Chopr...
MindMed Announces Project Angie, Targeting the Treatment of Pain with Psychedelics Canada NewsWire NEW YORK , May 5, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. ("MindMed" or the "Company") (NASDAQ: MNMD) (NEO: MMED), (DE: MMQ), a leading psychedelic-inspired medi...
A clinical-stage psychedelic medicine biotech company, Mind Medicine Inc. (MMEDF), has benefited from growing demand for therapies for people with mental disorders. However, several headwinds related to FDA approval and uncertainties surrounding its commercialization prospects could lead to a...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, June 9, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (NEO: MMED)(OTC:MMEDF)(DE: BGHM) (the “Company”), a leading clinical-stage pharmaceutical company and pioneer in the field of psychedelic inspired medicines, announces that J.R. Rahn, the Com...
Last week, Deepak Chopra revealed that he’d entered into a new partnership with MindMed (NEO: MMED) (OTCQB: MMEDF), which aligned with his continued interest in mind-body healing. MindMed is a clinical-stage biotech company that is researching psychedelic medicine. In his stat...